Key result
Valve-in-valve TAVR with Sapien S3 Ultra Resilia resolves a case of recurrent AI after Trilogy placement.
Why the study?
TAVR is increasingly used to treat aortic insufficiency, but management of recurrent AI after placement of the investigational Trilogy Valve is not well documented.
Case Report (n=1)
This case report demonstrates the feasibility of using a Sapien S3 Ultra Resilia valve for valve-in-valve TAVR to treat recurrent aortic insufficiency following initial Trilogy valve placement.
Offers potential bailout for recurrent AI after Trilogy; leaves open safety, efficacy, and durability in larger series.
Aortic insufficiency (AI) is the third most common left valvular heart disease. Transcatheter aortic valve replacement (TAVR) is becoming popular in the treatment of AI. The Trilogy Valve (JenaValve Technology, Irvine, California, United States) is in clinical trials. We report here a case of valve-in-valve TAVR with a Sapien S3 Ultra Resilia valve (Edwards Lifesciences Corporation, Irvine, California, United States) for recurrent AI after Trilogy valve placement.
No takes yet. Share an insight, caveat, or question.
Nispen et al. (2026) conducted a case report in Recurrent aortic insufficiency (n=1). Valve-in-valve TAVR with a Sapien S3 Ultra Resilia valve was evaluated. Valve-in-valve TAVR with a Sapien S3 Ultra Resilia valve was successfully used to treat a case of recurrent aortic insufficiency after Trilogy valve placement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: